Clinical Trial Outcomes
Uncertain results can delay or halt development
- Materiality
- high
Active Biotech
Active Biotech AB is a biotechnology company focused on developing first-in-class immunomodulatory treatments for oncology and immunology indications. The company is headquartered in Lund, Sweden, and is listed on NASDAQ Stockholm. Active Biotech's core projects include tasquinimod for hematological malignancies, laquinimod for inflammatory eye disorders, and naptumomab for solid tumors. Their strategy involves advancing these projects to clinical proof-of-concept and securing partnerships for further development and commercialization.
5
4.67
4.59
| % | |
|---|---|
| Oncology Treatments | 50% Includes tasquinimod and naptumomab for cancer treatment |
| Immunology Treatments | 30% Includes laquinimod for inflammatory eye disorders |
| Research and Development Services | 20% Clinical development and research services for drug development |
Active Biotech primarily serves pharmaceutical companies and research institutions seeking innovative treatments for...
- Pharmaceutical Companiesprimary
Collaborate on drug development and commercialization
- Research Institutionssecondary
Engage in clinical trials and research collaborations
- Biotechnology Partnersemerging
Partner for clinical development and market entry
Active Biotech is based in Lund, Sweden, and operates primarily in Europe and the United States...
- •Headquartered in Lund, Sweden
- •Clinical trials conducted in Europe and the US
- •Collaborations with European academic institutions
- •Strategic presence in key markets for oncology and immunology
Active Biotech's strategic priorities include advancing their clinical pipeline, securing partnerships for drug...
01
Advance Clinical Pipelinemedium-term
To reach proof-of-concept and attract partnerships
02
Establish Partnershipsshort-term
For development and commercialization support
03
Regulatory Approvalslong-term
To enable market entry and commercialization
Active Biotech faces significant risks related to pharmaceutical development, including clinical trial outcomes,...
Partnership Dependence
Essential for funding and commercialization
- Materiality
- high
Regulatory Approvals
Necessary for market entry
- Materiality
- high
Competition
Other firms may develop superior treatments
- Materiality
- medium
Revenue Recognition
Significant for financial results
Clinical Trial Expenses
High variability in costs
BioArctic
BIOA-B.ST · Health Care
BioArctic AB is a Swedish biopharmaceutical company focused on developing innovative treatments for severe neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS.
BioInvent International
BINV.ST · Health Care
BioInvent International is a biotechnology company focused on developing novel immuno-modulatory antibodies for cancer therapy.
CytomX Therapeutics, Inc.
CTMX · Pharmaceutical Preparations
CytomX Therapeutics is a clinical-stage biopharmaceutical company built around its PROBODY platform, which masks biologic drug activity until it reaches the tumor microenvironment.
Cantargia
CANTA.ST · Health Care
Cantargia is a Swedish biotechnology company focused on developing targeted antibody-based drugs for cancer, immunological, and other life-threatening diseases.
Aptose Biosciences Inc.
APTOF · Biological Products, (No Diagnostic Substances)
Nautilus Biotechnology, Inc.
NAUT · Laboratory Analytical Instruments
: 11/08/2026